Variability in the CIITA gene interacts with HLA in multiple sclerosis

Genes Immun. 2014 Apr-May;15(3):162-7. doi: 10.1038/gene.2013.71. Epub 2014 Jan 16.

Abstract

The human leukocyte antigen (HLA) is the main genetic determinant of multiple sclerosis (MS) risk. Within the HLA, the class II HLA-DRB1*15:01 allele exerts a disease-promoting effect, whereas the class I HLA-A*02 allele is protective. The CIITA gene is crucial for expression of class II HLA molecules and has previously been found to associate with several autoimmune diseases, including MS and type 1 diabetes. We here performed association analyses with CIITA in 2000 MS cases and up to 6900 controls as well as interaction analysis with HLA. We find that the previously investigated single-nucleotide polymorphism rs4774 is associated with MS risk in cases carrying the HLA-DRB1*15 allele (P=0.01, odds ratio (OR): 1.21, 95% confidence interval (CI): 1.04-1.40) or the HLA-A*02 allele (P=0.01, OR: 1.33, 95% CI: 1.07-1.64) and that these associations are independent of the adjacent confirmed MS susceptibility gene CLEC16A. We also confirm interaction between rs4774 and HLA-DRB1*15:01 such that individuals carrying the risk allele for rs4774 and HLA-DRB1*15:01 have a higher than expected risk for MS. In conclusion, our findings support previous data that variability in the CIITA gene affects MS risk, but also that the effect is modulated by MS-associated HLA haplotypes. These findings further underscore the biological importance of HLA for MS risk.

MeSH terms

  • Alleles
  • Case-Control Studies
  • Epistasis, Genetic*
  • Gene Frequency
  • Genetic Variation*
  • Genotype
  • HLA Antigens / genetics*
  • HLA Antigens / immunology
  • Humans
  • Linkage Disequilibrium
  • Multiple Sclerosis / epidemiology
  • Multiple Sclerosis / genetics*
  • Multiple Sclerosis / immunology
  • Nuclear Proteins / genetics*
  • Odds Ratio
  • Polymorphism, Single Nucleotide
  • Trans-Activators / genetics*

Substances

  • HLA Antigens
  • MHC class II transactivator protein
  • Nuclear Proteins
  • Trans-Activators